Skip to Content

Vincristine liposome Pregnancy and Breastfeeding Warnings

Vincristine liposome is also known as: Marqibo

Medically reviewed on August 6, 2018

Vincristine liposome Pregnancy Warnings

FDA pregnancy category: D

Use vincristine liposome only if clearly needed and benefit outweighs potential risk.

Women of childbearing age should use effective contraceptive measures during treatment.

Animal studies have revealed evidence of embryofetal toxicity (skeletal and visceral fetal malformations), decreases in fetal weights, increased numbers of early resorptions and post-implantation losses, and decreased maternal body weights. Animal studies indicate that vincristine liposome can impair male fertility, and can cause testicular degeneration and atrophy and epididymal aspermia. There are no controlled data in human pregnancy.

FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Vincristine liposome Breastfeeding Warnings

A decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Unknown

The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc, South San Francisco,, CA.

References for breastfeeding information

  1. "Product Information. Marqibo (vinCRIStine liposome)." Talon Therapeutics Inc, South San Francisco,, CA.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide